IMC 4023
Alternative Names: IMC-4023Latest Information Update: 21 Jul 2022
At a glance
- Originator ImmuneCyte
- Class Antineoplastics; Immunotherapies; Tumour infiltrating lymphocyte therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Malignant melanoma
Most Recent Events
- 19 Jul 2022 Preclinical trials in Malignant melanoma in USA (Parenteral),prior to July 2022 (Immunecyte pipeline, July 2022).